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ABSTRACT
Objectives: To analyse whether persistence of synovial B
lineage cells and lack of clinical response to rituximab
treatment in patients with rheumatoid arthritis (RA) are
associated with low rituximab serum levels and anti-
rituximab antibody (ARA) formation.
Methods: Fifty-eight patients with RA were treated with
rituximab. The clinical response was determined
24 weeks after each treatment course using the Disease
Activity Score evaluated in 28 joints (DAS28) and EULAR
response criteria. Rituximab serum levels, ARAs and
synovial B lineage cell numbers were determined before
and after treatment.
Results: Four weeks after treatment rituximab serum
levels were highly variable. Low rituximab levels were
associated with ARA formation (in five patients (8.6%))
and high baseline erythrocyte sedimentation rate.
Interestingly, serum rituximab levels were not related to
persistence of synovial B lineage cells or clinical response.
Furthermore, response to treatment and re-treatment was
similar in ARA-positive and ARA-negative patients.
Conclusion: There is clear variability in serum levels after
rituximab treatment, but rituximab levels are not lower in
patients with persistence of synovial B lineage cells or
lack of clinical response. The current treatment schedule
suffices to induce and maintain a clinical response, even
when ARAs are formed.
Rituximab is an effective treatment for rheumatoid
arthritis (RA).1 2 Recent studies have shown that
rituximab induces an incomplete B-cell depletion in
the synovial tissue of a subset of patients with
RA3–6 and that persistence of synovial B lineage
cells and (small numbers of) B-cell subsets in the
peripheral blood is associated with lack of clinical
response.7–9 This might theoretically be explained
by suboptimal rituximab levels in these patients
due to a high initial B-cell load, early formation of
anti-rituximab antibodies (ARAs) or other factors
influencing pharmacokinetics. Therefore, we ana-
lysed the relationship between these parameters in
a cohort of patients with RA starting rituximab
treatment. The data were confirmed in an inde-
pendent cohort.
PATIENTS AND METHODS
Patients
Patients were included from two studies on the
synovial tissue response to rituximab in RA that
were reported previously.5 6 Patients had active RA
(Disease Activity Score evaluated in 28 joints
(DAS2810 >3.2) despite methotrexate treatment.
The study protocol was approved by the ethics
committee of the participating centres; all patients
gave written informed consent.
Treatment regimen
Patients were treated with two infusions of
1000 mg rituximab (days 1 and 15). Pre-medication
with methylprednisolone was omitted in the
Academic Medical Centre/University of
Amsterdam (AMC) cohort.4 In both cohorts the
DAS28 was obtained at baseline and after
24 weeks. A clinically significant decrease in
disease activity was defined according to the
EULAR response criteria.11 Patients were re-treated
after at least 24 weeks.12
Measurement of rituximab levels and ARAs
Rituximab levels and ARAs were measured after 4,
12 and 24 weeks (Leiden University Medical
Centre (LUMC)) or 4, 16 and 24 weeks (AMC)
(for method, see online supplemental file).
Immunohistochemistry
Synovial biopsy specimens were collected by
arthroscopy in 17 patients of the LUMC cohort
and 24 patients of the AMC cohort as described
previously.6 7 In the AMC cohort frozen sections
were stained with anti-CD19 (Becton Dickinson,
San Jose, California, USA) and anti-CD22 (CLB-B-
ly; Central Laboratory of the Netherlands Red
Cross Blood Transfusion Service, Amsterdam, The
Netherlands) to detect B cells and anti-CD138
(clone B-B4; Immunotech, Marseille, France) to
detect plasma cells. In the LUMC cohort paraffin-
embedded sections were stained with anti-cyto-
plasmic CD20 (clone L26) to detect B cells, anti-
human CD79a (clone JCD117, both from Dako,
Heverlee, Belgium) for B and plasma cells, and anti-
human CD138 (clone B-B4; Serotec, Oxford, UK)
to detect plasma cells. The results of immunohis-
tochemical staining were quantified using digital
image analysis (AMC) or semiquantitative evalua-
tion (LUMC5 6), respectively. The relationship
between CD20+ B cells and rituximab levels was
only analysed for baseline samples, since rituximab
bound to CD20 might interfere with the detection
of B cells using anti-CD20.13
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Statistical analysis
Student paired t tests were used to evaluate the change in
DAS28 after treatment. Univariate linear and univariate logistic
regression analyses were calculated, where appropriate, to assess
the relationship first, between baseline patient characteristics,
ARAs and rituximab levels; second, between rituximab levels
and persistence of synovial B lineage cells; and third, between
rituximab serum levels, ARAs, and clinical response determined
by the decrease in DAS28 and the EULAR response (moderate/
good versus none).
RESULTS
Patient characteristics
Clinical response to the first and second treatment course was
available for a total of 58 and 47 patients, respectively. Table 1
shows the clinical characteristics and clinical response.
Variability in serum levels of rituximab and predictors of
variability
Rituximab levels measured 4 weeks after the first infusion were
remarkably variable with a range of 0.3–362 (median 110) mg/ml
(fig 1, left). ARAs were detectable in two patients who had
received methylprednisolone and in three who did not receive
this pre-medication. Since the incidence of ARA formation was
low, the two cohorts were combined, when possible, for further
analyses involving ARAs. Rituximab levels in ARA-positive
patients were lower than in ARA-negative patients, from
4 weeks after treatment (p=0.003, p=0.096, p=0.001 and
p,0.001 after 4, 12, 16 and 24 weeks, respectively; fig 1, right).
Baseline erythrocyte sedimentation rate negatively predicted
rituximab levels at week 4 in both patient cohorts (AMC
cohort: r2=20.17, p=0.018; LUMC cohort: r2=20.23,
p=0.007); in the AMC cohort similar trends were also found
for baseline C-reactive protein and DAS28 (for C-reactive
protein: r2=20.23, p=0.006; for DAS28: r2=20.13,
p=0.032). However, no relationship was found between
rituximab levels and the presence of synovial B cells (present
in 82% of patients (AMC cohort) and in 62% of patients
(LUMC cohort)), synovial CD138+ plasma cells (in, respec-
tively, 82% and 71% of patients), synovial CD79a+ B/plasma
cells (in 86% of patients (only the LUMC cohort)) or numbers of
CD19+ B cells in peripheral blood (data not shown).
Furthermore, no relationship was found between rituximab
levels after 4 weeks and body surface area, gender, use of oral
prednisolone, dosage of methotrexate, or use of methylpred-
nisolone pre-medication.
Table 1 Patient characteristics and clinical response
Demographics (n= 58) AMC (n=30) LUMC (n=28)
Female, n (%) 24 (80) 20 (71)
Baseline disease status
IgM-RF positive, n (%) 25 (83) 24 (86)
ACPA positive, n (%) 27 (90) 23 (82)
DAS28, mean (SD) 6.5 (1.1) 6.0 (1.2)
ESR (mm/h), median (range) 37 (4–86) 46 (5–139)
CRP (mg/dl), median (range) 29 (1.9–112) 25 (2.0–114)
Medication
Concomitant methotrexate, n (%) 30 (100) 21 (75)
Concomitant leflunomide, n (%) 0 (0) 1 (4)
Corticosteroids, n (%) 21 (70) 11 (39)
Clinical response 24 weeks after course 1
(n=58)
AMC (n=30) LUMC (n=28)
DAS28, mean (SD) 5.0 (1.9) 4.5 (1.2)
EULAR good (%) 4 (13) 7 (25)
EULAR moderate (%) 15 (50) 17 (61)
EULAR none (%) 11 (37) 4 (14)
Clinical response 24 weeks after course 2
(n=47)
AMC (n=22) LUMC (n=25)
DAS28, mean (SD) 4.5 (1.7) 3.9 (1.1)
EULAR good (%) 5 (23) 9 (36)
EULAR moderate (%) 10 (45) 14 (56)
EULAR none (%) 7 (32) 2 (8)
ACPA, anti-citrullinated peptide antibodies; AMC, Academic Medical Centre/University
of Amsterdam; CRP, C-reactive protein; DAS28, Disease Activity Score 28-joint
assessment; ESR, erythrocyte sedimentation rate; EULAR, European League Against
Rheumatism; IgM-RF, IgM rheumatoid factor; LUMC, Leiden University Medical
Centre.
Figure 1 Rituximab levels were measured in two cohorts comprising a total of 58 patients with rheumatoid arthritis, starting rituximab treatment (left,
rituximab levels after treatment in the combined cohorts). Anti-rituximab antibodies (ARAs) were detectable in five patients. The relationship between
rituximab levels and ARAs was calculated for the combined cohorts, since the incidence of ARAs was low. Rituximab levels in these patients were
significantly lower from 4 weeks after treatment (right). Data are represented by geometric means and 95% confidence intervals; *p,0.05. While
rituximab clearance was highly variable, neither ARA formation nor rituximab serum levels were related to the clinical response at week 24.
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Synovial B cells persist despite detectable rituximab levels in
peripheral blood
In the AMC cohort the change in synovial CD19+ and CD22+ B
cells was analysed 4 and 16 weeks after initiation of treatment.
A marked decrease in synovial B cells was found 4 weeks after
the first infusion. While in some patients a further decrease in B
cells occurred, at the group level B cells did not decrease further.
Synovial B cells persisted in a subset of patients (in 47% and
35% of patients after 4 and 16 weeks, respectively). We
compared serum rituximab levels in patients with persistence
of synovial B cells at week 4 with those in patients without
detectable synovial B cells at that time point (ie, 2 weeks after
the second infusion when therapeutically active levels of
rituximab are expected). Of interest, serum rituximab levels
did not differ between these groups (supplementary table; fig 2,
Figure 2 Analysis of the relationship between the persistence of synovial B cells and rituximab levels and influence of anti-rituximab antibody (ARA)
formation on the clinical response. At week 4 (2 weeks after the second infusion) rituximab levels were similar in patients with persistence of synovial
B cells and in those without detectable synovial B cells (top left, CD19+ B cells in the Academic Medical Centre/University of Amsterdam (AMC)
cohort; data shown for patients with synovial B cells at baseline). Rituximab levels also did not differ between patients with a subsequent decrease or
persistence of synovial B cells (top right, CD19+ B cells in AMC cohort; data shown for patients with synovial B cells at baseline). The relationship
between ARAs and clinical response was calculated for the combined cohorts, since the incidence of ARAs was low. In patients who formed ARAs,
clinical response to a first (bottom left) and a second treatment course (bottom right) did not differ from the response in patients without ARAs.
Table 2 Prediction of decrease in synovial B lineage cells by rituximab
(RTX) levels at week 4
RTX levels week 4
Persistence of CD22+ B cells at week 4* 0.10
Persistence of CD19+ B cells at week 4* 0.53
Change in CD22+ B cells weeks 4–16* 0.45
Change in CD19+ B cells weeks 4–16* 0.70
Change in CD138+ plasma cells weeks 4–16* 0.43
Change in CD79+ B/plasma cells weeks 0–12{ 0.20
Change in CD138+ plasma cells weeks 0–12{ 0.98
Logistic regression analysis was used to calculate the relationship between rituximab
levels and persistence of synovial B cells at week 4; linear regression analysis was
used to calculate the relationship between rituximab levels at week 4 and the
subsequent change in synovial B lineage cells.
*Academic Medical Centre/University of Amsterdam; {Leiden University Medical
Centre.
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top left). Similarly, the rituximab levels at week 4 did not
predict whether synovial B cells persisted or decreased further
after 16 weeks (fig 2, top right). Also, rituximab levels at week 4
did not predict the persistence of plasma cells at week 16.
These data were confirmed in the LUMC cohort. Rituximab
levels at weeks 4 or 12 did not correlate with persistence of
synovial CD79+ B cells or CD138+ plasma cells (table 2).
Variability in rituximab levels and ARA formation are not related
to the clinical response to rituximab
Consistent with the results presented above clinical non-
responders did not have lower rituximab levels than responders
(AMC: p=0.81, p=0.33 for weeks 4 and 16; LUMC: p=0.58,
p=0.11 for weeks 4 and 12). ARA-positive patients experienced
a decrease in DAS28 and EULAR response 24 weeks after the
first and second treatment course similar to that of ARA-
negative patients (p=0.87 and p=0.32, for the response to
courses 1 and 2, respectively; fig 2, bottom, left and right).
DISCUSSION
We examined whether persistence of synovial B lineage cells and
lack of clinical response are related to low rituximab serum
levels. We show that ARA formation and differences in baseline
disease activity are partly responsible for a marked variability in
serum rituximab levels after treatment. Nevertheless, patients
with ARAs or relatively low rituximab levels experience, on
average, a depletion of synovial B lineage cells and a clinical
response similar to those of patients without ARAs or higher
serum levels of rituximab.
The relationship between rituximab levels, ARAs and
systemic inflammation is in line with earlier observations in
patients treated with infliximab.14 Conceivably, patients with
high systemic inflammation have a higher B-cell load, although
we found no direct correlation with synovial or circulating B-
cell numbers. Alternatively, (therapeutic) antibodies might be
cleared more rapidly in these patients.
The data suggest that persistence of B cells after rituximab
may be explained by expression of local survival factors rather
than suboptimal rituximab levels. Furthermore, the current
rituximab treatment regimen results in drug levels that remain
in the therapeutic range (defined by response as indicated by
clinical signs and symptoms) even when patients form ARAs.
These findings are in line with two dose-ranging studies that
showed no statistically significant difference in ACR20, ACR50,
or ACR70 response between patients treated with 26500 mg
and those treated with 261000 mg rituximab.1 15 It should be
noted that the group of ARA-positive patients was relatively
small and that higher serum levels might perhaps result in a
clinical response of longer duration. This study was not
designed to examine this possibility, since all patients were re-
treated after 24 weeks if DAS28 was >3.2.12 Other limitations
include the lack of data on rituximab levels at earlier time points
and data on drug levels in the synovium. Although the data
suggest that perhaps lower doses of rituximab might be used in
some patients, it is obviously too early to recommend this for
clinical practice until more data on the effects of both clinical
signs and symptoms and structural outcomes become available.
Moreover, there is a clear need for the identification of
biomarkers that may help to further optimise rituximab
treatment in individual patients.
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